BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...Checkmate raised $85 million in a series C round to advance lead program CMP-001 across a...
...as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners, and Decheng Capital. CMP-001...
...increase the efficacy of checkpoint inhibitors. Last year, the company reported Phase I data showing CMP-001...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BioCentury | Dec 14, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...and CEO of innate immune activation company Biothera Pharmaceuticals Inc. (Eagan, Minn.). Checkmate's lead compound, CMP-001...
...treatment. At April's American Association for Cancer Research meeting in Chicago, Checkmate reported that intratumoral CMP-001...
...into late 2019. Checkmate has raised $74 million to date. Checkmate Pharmaceuticals Inc., Cambridge, Mass. Allison Johnson CMP-001...
BioCentury | Dec 13, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...and CEO of innate immune activation company Biothera Pharmaceuticals Inc. (Eagan, Minn.). Checkmate's lead compound, CMP-001...
...treatment. At April's American Association for Cancer Research meeting in Chicago, Checkmate reported that intratumoral CMP-001...
...said. The funds provide runway into late 2019. Checkmate has raised $74 million to date. Allison Johnson CMP-001...
BioCentury | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

...our trials,” he said. Checkmate recently reported positive Phase I data from its TLR9 agonist CMP-001...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

...patients so that those who didn’t respond before will.” Checkmate’s toll-like receptor 9 (TLR9) agonist CMP-001...
...single-arm studies if you have the right patients.” Michael Gladstone, Atlas Venture Checkmate’s lead candidate CMP-001...
...that among 69 evaluable patients with advanced metastatic melanoma that is resistant to PD-1/PD-L1 inhibitors, CMP-001...
BioCentury | Apr 20, 2018
Clinical News

Checkmate's CMP-001 among TLR9 agonist combo data highlighted at AACR

...Mass.) reported data from the CMP-001 plus Keytruda arm of the open-label, U.S. Phase Ib CMP-001-001...
...rate to PD-1/PD-L1 monotherapy in this population is about 6%. Among 69 evaluable patients, intratumoral CMP-001...
...registration pathway for CMP-001 with FDA, which could include seeking accelerated approval of the candidate. CMP-001...
BioCentury | Apr 17, 2018
Clinical News

Checkmate's CMP-001 among TLR9 agonist combo data highlighted at AACR

...Inc. (Cambridge, Mass.) reported data from the CMP-001 plus Keytruda arm of the Phase Ib CMP-001-001...
...rate to PD-1/PD-L1 monotherapy in this population is about 6%. Among 69 evaluable patients, intratumoral CMP-001...
...registration pathway for CMP-001 with FDA, which could include seeking accelerated approval of the candidate. CMP-001...
BioCentury | Oct 6, 2017
Clinical News

Mateon discontinuing Zybrestat on Phase II/III ovarian cancer data

Mateon Therapeutics Inc. (OTCQX:MATN) discontinued development of Zybrestat fosbretabulin (combretastatin A4P, CA4P) after data from the first 70 platinum-resistant ovarian cancer patients enrolled in the Phase II/III FOCUS trial showed Zybrestat in combination with physician’s...
BioCentury | Sep 1, 2017
Clinical News

Mateon reports interim Phase II/III data for Zybrestat in ovarian cancer

Mateon Therapeutics Inc. (OTCQX:MATN) reported data from a second scheduled interim analysis of the first 40 patients with platinum resistant ovarian cancer in the Phase II/III FOCUS trial of Zybrestat fosbretabulin (combretastatin A4P, CA4P) to...
Items per page:
1 - 10 of 37